DXSE:XETRA:XETRA-Xtrackers - Stoxx Europe 600 Health Care Swap UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 226.15

Change

0.00 (0.00)%

Market Cap

USD 0.14B

Volume

426.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-04-27 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

-0.04 (-0.08%)

USD 448.39B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

-0.01 (-0.05%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

-0.03 (-0.10%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

-0.03 (-0.09%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

-0.05 (-0.21%)

USD 157.79B
TM5:XETRA T-MOBILE US INC.DL-00001

+0.58 (+0.38%)

USD 126.93B
8R80:XETRA Amundi Index Solutions - Amund..

+0.64 (+0.46%)

USD 102.14B
JARI:XETRA Amundi Index Solutions - Amund..

+0.15 (+0.34%)

USD 101.29B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

-0.04 (-0.07%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

+1.32 (+0.26%)

USD 80.38B

ETFs Containing DXSE:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 9.86% 82% B 79% B-
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.86% 82% B 79% B-
Trailing 12 Months  
Capital Gain 10.59% 55% F 59% D-
Dividend Return N/A N/A N/A N/A N/A
Total Return 10.59% 55% F 58% F
Trailing 5 Years  
Capital Gain 66.68% 84% B 82% B
Dividend Return N/A N/A N/A N/A N/A
Total Return 66.68% 84% B 80% B-
Average Annual (5 Year Horizon)  
Capital Gain 8.76% 72% C 69% C-
Dividend Return 8.76% 71% C- 67% D+
Total Return N/A 15% F 21% F
Risk Return Profile  
Volatility (Standard Deviation) 8.52% 67% D+ 74% C
Risk Adjusted Return 102.74% 99% N/A 99% N/A
Market Capitalization 0.14B 42% F 38% F

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.